Chemotherapy-induced anemia (CIA) patients enrolled in the study received a once daily oral dose of PBI-1402 during a period of eight weeks while undergoing their normal course of chemotherapy. All patients enrolled have completed the PBI-1402 treatment period. Only two patients out of 28 (7%) treated with PBI-1402 required a red blood cell (RBC) transfusion, a response rate greater than 90% with regards to this clinical objective.
Pierre Laurin, president and CEO of ProMetic, said: “These results are very exciting and meet the primary objective that formed the basis for FDA approval of other erythropoiesis-stimulating agents (ESAs) in CIA patients. This new encouraging data further supports the potential role PBI-1402 could play in the management of anemia in patients with cancer.”